High-throughput proteomics has advanced markedly in both sample throughput and proteome depth. Paired with recent gains in plasma proteomics, these capabilities now enable large-scale studies across clinical trials, population-health cohorts, and the development of extensive proteomic reference databases. In this report, we evaluate a multi-cancer cohort using both Olink HT and Proteograph XT Astral MS workflows; our findings are supported by a recent CPTAC pan-cancer publication.
